LLY

1,160.91

-0.46%↓

JNJ

233.45

+0.31%↑

ABBV

225.14

+0.46%↑

UNH

412.56

+2.41%↑

MRK

119.25

-1.47%↓

LLY

1,160.91

-0.46%↓

JNJ

233.45

+0.31%↑

ABBV

225.14

+0.46%↑

UNH

412.56

+2.41%↑

MRK

119.25

-1.47%↓

LLY

1,160.91

-0.46%↓

JNJ

233.45

+0.31%↑

ABBV

225.14

+0.46%↑

UNH

412.56

+2.41%↑

MRK

119.25

-1.47%↓

LLY

1,160.91

-0.46%↓

JNJ

233.45

+0.31%↑

ABBV

225.14

+0.46%↑

UNH

412.56

+2.41%↑

MRK

119.25

-1.47%↓

LLY

1,160.91

-0.46%↓

JNJ

233.45

+0.31%↑

ABBV

225.14

+0.46%↑

UNH

412.56

+2.41%↑

MRK

119.25

-1.47%↓

Home・Stock List・Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Open

SectorHealthcare

34.58 4.31

Buy Sell

Overview

Share price change

24h

Current

Min

33.16

Max

34.64

Key metrics
By Trading Economics
Income	-5M -128M
Sales	6.8M 11M
EPS	-1.23
Profit margin	-1,191.029
Employees	594
EBITDA	-18M -139M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+167.74% upside

Dividends
By Dow Jones
Next Earnings	6 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-710M 3.6B
Previous open	30.27
Previous close	34.58

News Sentiment

By Acuity

43%

57%

142 / 344 Healthcare

Crinetics Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

8 Jun 2026, 22:20 UTC

Acquisitions, Mergers, Takeovers

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8 Jun 2026, 15:41 UTC

Major Market Movers

American Battery Shares Jump on Energy Department Victory

8 Jun 2026, 23:46 UTC

Market Talk

Nikkei May Rebound After Monday's Selloff -- Market Talk

8 Jun 2026, 23:37 UTC

Market Talk

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8 Jun 2026, 23:25 UTC

Market Talk

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8 Jun 2026, 23:25 UTC

Market Talk

Global Equities Roundup: Market Talk

8 Jun 2026, 21:57 UTC

Acquisitions, Mergers, Takeovers

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8 Jun 2026, 21:56 UTC

Acquisitions, Mergers, Takeovers

Salesforce Agrees to Buy m3ter

8 Jun 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

8 Jun 2026, 19:22 UTC

Market Talk

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8 Jun 2026, 19:01 UTC

Market Talk

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8 Jun 2026, 18:52 UTC

Market Talk

Global Energy Roundup: Market Talk

8 Jun 2026, 18:52 UTC

Market Talk

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8 Jun 2026, 18:17 UTC

Market Talk

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8 Jun 2026, 17:32 UTC

Market Talk

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8 Jun 2026, 17:29 UTC

Market Talk

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8 Jun 2026, 17:29 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 Jun 2026, 16:55 UTC

Acquisitions, Mergers, Takeovers

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8 Jun 2026, 16:54 UTC

Acquisitions, Mergers, Takeovers

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8 Jun 2026, 16:40 UTC

Market Talk

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8 Jun 2026, 16:31 UTC

Market Talk

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8 Jun 2026, 16:27 UTC

Market Talk

Mexican Inflation Seen Easing in May -- Market Talk

8 Jun 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 Jun 2026, 16:03 UTC

Acquisitions, Mergers, Takeovers

Orange Bought Stake From Lorca

8 Jun 2026, 16:01 UTC

Acquisitions, Mergers, Takeovers

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8 Jun 2026, 16:01 UTC

Acquisitions, Mergers, Takeovers

Orange Acquires 100% Ownership of MasOrange

8 Jun 2026, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

8 Jun 2026, 15:58 UTC

Market Talk

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8 Jun 2026, 15:55 UTC

Market Talk

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8 Jun 2026, 15:41 UTC

Market Talk

Gold Falls Below 200-Day Moving Average -- Market Talk

Peer Comparison

Price change

Crinetics Pharmaceuticals Inc Forecast

Price Target

By TipRanks

167.74% upside

12 Months Forecast

Average 88.14 USD 167.74%

High 97 USD

Low 81 USD

Based on 8 Wall Street analysts offering 12 month price targets forCrinetics Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Crinetics Pharmaceuticals Inc - Dist in the past 3 months.

Sentiment

By Acuity

142 / 344 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.